Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.62 |
| ▸ | BRAF | P15056 | 4/20 | 0.55 |
| ▸ | RAF1 | P04049 | 1/20 | 0.55 |
| ▸ | YES1 | P07947 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | CCR2 | P41597 | 1/20 | 0.45 |
| ▸ | CCR5 | P51681 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27682678 | 0.91 | MAPK14 (0.66) | MAPK14BRAFRAF1YES1KDM4E | |
| SCHEMBL4168270 | 0.88 | MAPK14 (0.62) | MAPK14BRAFRAF1YES1KDM4E | |
| SCHEMBL4168731 | 0.86 | MAPK14 (0.68) | MAPK14BRAFRAF1YES1KDM4E | |
| SCHEMBL27682670 | 0.84 | BRAF (0.69) | MAPK14BRAFRAF1YES1KDM4E | |
| SCHEMBL27682654 | 0.83 | MAPK14 (0.64) | MAPK14BRAFRAF1YES1KDM4E | |
| SCHEMBL27682665 | 0.83 | MAPK14 (0.65) | MAPK14BRAFRAF1YES1KDM4E | |
| SCHEMBL4164155 | 0.83 | BRAF (0.65) | MAPK14BRAFRAF1YES1KDM4E | |
| SCHEMBL4177014 | 0.82 | BRAF (0.58) | MAPK14BRAFRAF1YES1KDM4E | |
| SCHEMBL3881854 | 0.82 | CDK8 (0.57) | MAPK14BRAFRAF1KDM4EALDH1A1 | |
| SCHEMBL27682671 | 0.82 | MAPK14 (0.69) | MAPK14BRAFRAF1YES1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163525-A1 | SUBSTITUTED QUINAZOLINES WITH ANTI-CANCER ACTIVITY | ASTRAZENECA AB (SE) | 2009-06-25 | — | — | US | claimed |
| EP-2007736-A1 | SUBSTITUTED QUINAZOLINES WITH ANTI-CANCER ACTIVITY | AstraZeneca AB (SE) | 2008-12-31 | — | — | EP | claimed |
| WO-2007113557-A1 | SUBSTITUTED QUINAZOLINES WITH ANTI-CANCER ACTIVITY | ASTRAZENECA AB (SE) | 2007-10-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163525-A1 | SUBSTITUTED QUINAZOLINES WITH ANTI-CANCER ACTIVITY | BRAF, NRAS, RAF1 | MAPK14 213/4885BRAF 1/4885RAF1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.